DONGWHA PHARM.CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8,720 KRW | -0.34% |
|
+0.23% | -15.09% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 251,230 | 229,420 | 542,492 | 404,115 | 256,309 | 284,265 |
| Enterprise Value (EV) 1 | 147,563 | 116,311 | 437,850 | 294,080 | 155,278 | 242,536 |
| P/E ratio | 25 x | 24.4 x | 19 x | 22.6 x | 12.6 x | 10.4 x |
| Yield | 1.32% | 1.44% | 0.92% | 1.23% | 1.94% | 1.75% |
| Capitalization / Revenue | 0.82 x | 0.75 x | 1.99 x | 1.38 x | 0.75 x | 0.79 x |
| EV / Revenue | 0.48 x | 0.38 x | 1.61 x | 1 x | 0.46 x | 0.67 x |
| EV / EBITDA | 6.53 x | 5.44 x | 13 x | 8.5 x | 3.66 x | 7.45 x |
| EV / FCF | -32.2 x | 8.35 x | 106 x | 32.6 x | 243 x | -17.3 x |
| FCF Yield | -3.1% | 12% | 0.94% | 3.07% | 0.41% | -5.79% |
| Price to Book | 0.85 x | 0.76 x | 1.64 x | 1.16 x | 0.7 x | 0.77 x |
| Nbr of stocks (in thousands) | 27,608 | 27,608 | 27,608 | 27,679 | 27,679 | 27,679 |
| Reference price 2 | 9,100 | 8,310 | 19,650 | 14,600 | 9,260 | 10,270 |
| Announcement Date | 3/13/19 | 3/11/20 | 3/17/21 | 3/22/22 | 3/15/23 | 3/19/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 306,603 | 307,150 | 272,075 | 293,018 | 340,426 | 361,109 |
| EBITDA 1 | 22,586 | 21,367 | 33,785 | 34,591 | 42,424 | 32,562 |
| EBIT 1 | 11,229 | 9,883 | 23,078 | 22,499 | 29,915 | 18,666 |
| Operating Margin | 3.66% | 3.22% | 8.48% | 7.68% | 8.79% | 5.17% |
| Earnings before Tax (EBT) 1 | 14,539 | 16,608 | 33,638 | 26,527 | 23,086 | 36,956 |
| Net income 1 | 10,069 | 9,402 | 28,508 | 17,870 | 20,383 | 27,438 |
| Net margin | 3.28% | 3.06% | 10.48% | 6.1% | 5.99% | 7.6% |
| EPS 2 | 364.7 | 340.6 | 1,033 | 646.7 | 736.4 | 991.1 |
| Free Cash Flow 1 | -4,576 | 13,932 | 4,131 | 9,028 | 639.2 | -14,039 |
| FCF margin | -1.49% | 4.54% | 1.52% | 3.08% | 0.19% | -3.89% |
| FCF Conversion (EBITDA) | - | 65.2% | 12.23% | 26.1% | 1.51% | - |
| FCF Conversion (Net income) | - | 148.17% | 14.49% | 50.52% | 3.14% | - |
| Dividend per Share 2 | 120.0 | 120.0 | 180.0 | 180.0 | 180.0 | 180.0 |
| Announcement Date | 3/13/19 | 3/11/20 | 3/17/21 | 3/22/22 | 3/15/23 | 3/19/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 103,667 | 113,110 | 104,642 | 110,036 | 101,031 | 41,729 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -4,576 | 13,932 | 4,131 | 9,028 | 639 | -14,039 |
| ROE (net income / shareholders' equity) | 3.39% | 3.14% | 8.92% | 5.55% | 5.83% | 7.17% |
| ROA (Net income/ Total Assets) | 1.9% | 1.65% | 3.56% | 3.19% | 4.11% | 2.27% |
| Assets 1 | 529,253 | 568,282 | 800,620 | 560,218 | 495,466 | 1,206,715 |
| Book Value Per Share 2 | 10,761 | 10,898 | 11,999 | 12,534 | 13,165 | 13,413 |
| Cash Flow per Share 2 | 1,471 | 1,368 | 2,122 | 2,185 | 1,241 | 2,609 |
| Capex 1 | 3,458 | 4,797 | 34,246 | 21,944 | 18,428 | 24,541 |
| Capex / Sales | 1.13% | 1.56% | 12.59% | 7.49% | 5.41% | 6.8% |
| Announcement Date | 3/13/19 | 3/11/20 | 3/17/21 | 3/22/22 | 3/15/23 | 3/19/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -15.09% | 176M | |
| +19.27% | 43.75B | |
| +27.47% | 22.06B | |
| +15.11% | 14.46B | |
| +12.33% | 13.62B | |
| +38.36% | 11.61B | |
| -9.54% | 6.9B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +9.64% | 5.32B |
- Stock Market
- Equities
- A000020 Stock
- Financials Dongwha Pharm.Co.,Ltd
